| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 10/11/2023 | 20.92% | Truist Securities | $16 → $15 | Maintains | Hold |
| 05/09/2023 | 20.92% | Truist Securities | $17 → $15 | Maintains | Hold |
| 02/22/2023 | 85.41% | Credit Suisse | $27 → $23 | Maintains | Outperform |
| 12/05/2022 | 117.65% | Credit Suisse | $28 → $27 | Maintains | Outperform |
| 11/16/2022 | 37.04% | Mizuho | $21 → $17 | Maintains | Neutral |
| 11/04/2022 | 28.98% | SVB Leerink | $20 → $16 | Maintains | Market Perform |
| 08/11/2022 | 125.72% | Credit Suisse | $30 → $28 | Maintains | Outperform |
| 08/10/2022 | 85.41% | BMO Capital | $25 → $23 | Maintains | Market Perform |
| 05/12/2022 | 61.23% | SVB Leerink | $24 → $20 | Maintains | Market Perform |
| 05/03/2022 | 141.84% | Credit Suisse | $31 → $30 | Maintains | Outperform |
| 05/02/2022 | 85.41% | Mizuho | $28 → $23 | Maintains | Neutral |
| 04/27/2022 | 93.47% | SVB Leerink | $27 → $24 | Maintains | Market Perform |
| 02/23/2022 | 149.9% | Credit Suisse | $32 → $31 | Maintains | Outperform |
| 12/22/2021 | 157.96% | Credit Suisse | $33 → $32 | Maintains | Outperform |
| 11/04/2021 | 117.65% | SVB Leerink | $29 → $27 | Maintains | Market Perform |
| 09/27/2021 | 133.78% | SVB Leerink | → $29 | Initiates Coverage On | → Market Perform |
| 08/09/2021 | 157.96% | Mizuho | $30 → $32 | Maintains | Neutral |
| 05/24/2021 | 174.08% | Citigroup | $22 → $34 | Maintains | Neutral |
| 05/10/2021 | 93.47% | Deutsche Bank | $17.5 → $24 | Maintains | Sell |
| 02/19/2021 | 101.53% | Credit Suisse | $26 → $25 | Maintains | Outperform |
| 10/19/2020 | -3.26% | Deutsche Bank | $20 → $12 | Downgrades | Hold → Sell |
| 10/06/2020 | 12.86% | UBS | $11 → $14 | Maintains | Sell |
| 06/08/2020 | 93.47% | Credit Suisse | $20 → $24 | Maintains | Outperform |
| 05/21/2020 | 37.04% | SunTrust Robinson Humphrey | $15 → $17 | Maintains | Hold |
| 05/11/2020 | 20.92% | CFRA | $22 → $15 | Maintains | Hold |
| 05/11/2020 | 61.23% | Credit Suisse | $22 → $20 | Maintains | Outperform |
| 05/08/2020 | -11.33% | UBS | $18 → $11 | Maintains | Sell |
| 04/21/2020 | 28.98% | Baird | $21 → $16 | Maintains | Neutral |
| 04/13/2020 | 20.92% | SunTrust Robinson Humphrey | $22 → $15 | Maintains | Hold |
| 03/26/2020 | 77.35% | Credit Suisse | $29 → $22 | Maintains | Outperform |
| 03/03/2020 | 69.29% | Baird | $24 → $21 | Maintains | Neutral |
| 02/24/2020 | 133.78% | Credit Suisse | $33 → $29 | Maintains | Outperform |
| 02/24/2020 | 61.23% | JP Morgan | $33 → $20 | Maintains | Neutral |
| 02/21/2020 | 77.35% | Mizuho | $25 → $22 | Maintains | Neutral |
| 02/21/2020 | 85.41% | Citigroup | $29 → $23 | Maintains | Neutral |
| 01/03/2020 | 133.78% | Citigroup | → $29 | Downgrades | Buy → Neutral |
| 12/20/2019 | 166.02% | JP Morgan | $26 → $33 | Maintains | Neutral |
| 12/18/2019 | 141.84% | SunTrust Robinson Humphrey | $27 → $30 | Maintains | Hold |
| 12/12/2019 | 166.02% | Stifel | $25 → $33 | Upgrades | Hold → Buy |
| 10/18/2019 | 45.1% | UBS | $19 → $18 | Maintains | Sell |
| 09/06/2019 | — | B of A Securities | Downgrades | Neutral → Underperform | |
| 08/27/2019 | 125.72% | Credit Suisse | $30 → $28 | Maintains | Outperform |
| 08/05/2019 | 101.53% | BMO Capital | $32 → $25 | Maintains | Market Perform |
| 08/02/2019 | 93.47% | Mizuho | $26 → $24 | Maintains | Neutral |
| 02/13/2019 | 238.57% | Credit Suisse | $44 → $42 | Maintains | Outperform |
| 01/15/2019 | — | Citigroup | Upgrades | Neutral → Buy | |
| 01/03/2019 | 174.08% | Deutsche Bank | → $34 | Initiates Coverage On | → Hold |
| 11/16/2018 | 198.27% | UBS | → $37 | Initiates Coverage On | → Sell |
| 11/06/2018 | 303.06% | Credit Suisse | $55 → $50 | Maintains | Outperform |
| 11/02/2018 | 222.45% | Baird | $48 → $40 | Maintains | Neutral |
| 11/02/2018 | 246.63% | BMO Capital | $48 → $43 | Maintains | Market Perform |
| 10/19/2018 | 286.94% | Baird | $50 → $48 | Maintains | Neutral |
What is the target price for Pediatrix Medical Group (MD)?
The latest price target for Pediatrix Medical Group (NYSE: MD) was reported by Truist Securities on October 11, 2023. The analyst firm set a price target for $15.00 expecting MD to rise to within 12 months (a possible 20.92% upside). 6 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Pediatrix Medical Group (MD)?
The latest analyst rating for Pediatrix Medical Group (NYSE: MD) was provided by Truist Securities, and Pediatrix Medical Group maintained their hold rating.
When is the next analyst rating going to be posted or updated for Pediatrix Medical Group (MD)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Pediatrix Medical Group, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Pediatrix Medical Group was filed on October 11, 2023 so you should expect the next rating to be made available sometime around October 11, 2024.
Is the Analyst Rating Pediatrix Medical Group (MD) correct?
While ratings are subjective and will change, the latest Pediatrix Medical Group (MD) rating was a maintained with a price target of $16.00 to $15.00. The current price Pediatrix Medical Group (MD) is trading at is $12.41, which is out of the analyst's predicted range.